BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 8735174)

  • 1. Terazosin: ex vivo and in vitro platelet aggregation effects in patients with arterial hypertension.
    Hernández Hernández R; Angeli-Greaves M; Carvajal AR; Guerrero Pajuelo J; Armas Padilla MC; Armas-Hernández MJ
    Am J Hypertens; 1996 May; 9(5):437-44. PubMed ID: 8735174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence of an antiplatelet aggregation action of doxazosin in patients with hypertension: an ex vivo study.
    Hernandez Hernandez R; Guerrero Pajuelo JR; Carvajal AR; Armas Padilla MC; Armas de Hernandez MJ; Barragan O; Boada Boada JJ
    Am Heart J; 1991 Jan; 121(1 Pt 2):395-401. PubMed ID: 1824666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of terazosine and atenolol on serum lipids in essential hypertension].
    Bur A; Woisetschläger C; Herkner H; Derhaschnig U; Quehenberger P; Hirschl MM
    Z Kardiol; 2002 Sep; 91(9):685-92. PubMed ID: 12448067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of doxazosin on platelet aggregation in normotensive subjects and patients with hypertension: an in vitro study.
    Hernandez Hernandez R; Carvajal AR; Guerrero Pajuelo J; Armas de Hernandez MJ; Armas Padilla MC; Barragan O; Boada Boada JJ; Roa E
    Am Heart J; 1991 Jan; 121(1 Pt 2):389-94. PubMed ID: 1824665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings.
    Itskovitz HD
    Clin Ther; 1994; 16(3):490-504. PubMed ID: 7923316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha-1 adrenoceptor blockade with doxazosin in hypertension: effects on blood pressure and lipoproteins.
    Ames RP; Kiyasu JY
    J Clin Pharmacol; 1989 Feb; 29(2):123-7. PubMed ID: 2565917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effects of doxazosin and hydrochlorothiazide on serum lipids and blood pressure in essential hypertension.
    Trost BN; Weidmann P; Riesen W; Claessens J; Streulens Y; Nelemans F
    Am J Cardiol; 1987 May; 59(14):99G-104G. PubMed ID: 2884861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of antihypertensive and lipid actions of terazosin and atenolol in essential hypertension.
    Silke B; Guy S; Humphreys JE
    J Hum Hypertens; 1992 Jun; 6(3):221-5. PubMed ID: 1352828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin.
    Hayduk K; Schneider HT
    Am J Cardiol; 1987 May; 59(14):95G-98G. PubMed ID: 2884860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group.
    Grimm RH; Flack JM; Grandits GA; Elmer PJ; Neaton JD; Cutler JA; Lewis C; McDonald R; Schoenberger J; Stamler J
    JAMA; 1996 May 22-29; 275(20):1549-56. PubMed ID: 8622245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of terazosin and methyclothiazide on blood pressure and serum lipids.
    Luther RR; Glassman HN; Estep CB; Maurath CJ; Jordan DC
    Am Heart J; 1989 Apr; 117(4):842-7. PubMed ID: 2564723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Terazosin: a new antihypertensive agent with favorable effects on lipids.
    Luther RR
    Int J Clin Pharmacol Ther Toxicol; 1989 Jul; 27(7):313-9. PubMed ID: 2570758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicentre, hospital study of the efficacy and safety of terazosin and its effects on the plasma cholesterol levels of patients with essential hypertension.
    Lytle TB; Coles SJ; Waite MA
    J Clin Pharm Ther; 1991 Aug; 16(4):263-73. PubMed ID: 1682328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive therapy with once-daily administration of terazosin, a new alpha 1-adrenergic-receptor blocker.
    Abraham PA; Halstenson CE; Matzke GR; Napier JL; Keane WF
    Pharmacotherapy; 1985; 5(5):285-9. PubMed ID: 2866492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of terazosin on serum lipids.
    Deger G
    Am J Med; 1986 May; 80(5B):82-5. PubMed ID: 2872813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience with doxazosin in general medical practice.
    Rosenthal J
    Am Heart J; 1988 Dec; 116(6 Pt 2):1748-57. PubMed ID: 2904745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension.
    Torvik D; Madsbu HP
    Am J Cardiol; 1987 May; 59(14):68G-72G. PubMed ID: 2884855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind parallel trial to assess the efficacy of doxazosin, atenolol and placebo in patients with mild to moderate systemic hypertension.
    Nash DT; Schonfeld G; Reeves RL; Black H; Weidler DJ
    Am J Cardiol; 1987 May; 59(14):87G-90G. PubMed ID: 2884859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxazosin in the treatment of mild and moderate essential hypertension in general medical practice.
    van den Hogen AL
    Am Heart J; 1988 Dec; 116(6 Pt 2):1757-62. PubMed ID: 2904746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension.
    Titmarsh S; Monk JP
    Drugs; 1987 May; 33(5):461-77. PubMed ID: 2885169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.